Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.

Novartis NVS announced that the FDA approved a label expansion of psoriasis drug Cosentyx. The regulatory body approved the ...

US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...

Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...